243 related articles for article (PubMed ID: 30408786)
1. Depression Symptoms Predict Worse Clinical Response to Etanercept Treatment in Psoriasis Patients.
Jin W; Zhang S; Duan Y
Dermatology; 2019; 235(1):55-64. PubMed ID: 30408786
[TBL] [Abstract][Full Text] [Related]
2. Etanercept reduces anxiety and depression in psoriasis patients, and sustained depression correlates with reduced therapeutic response to etanercept.
Yang A; Xin X; Yang W; Li M; Yang W; Li L; Liu X
Ann Dermatol Venereol; 2019 May; 146(5):363-371. PubMed ID: 31047699
[TBL] [Abstract][Full Text] [Related]
3. IL-1β, IL-17A and combined phototherapy predicts higher while previous systemic biologic treatment predicts lower treatment response to etanercept in psoriasis patients.
Liu Y; Qin G; Meng Z; Du T; Wang X; Tang Y; Cao J
Inflammopharmacology; 2019 Feb; 27(1):57-66. PubMed ID: 30242748
[TBL] [Abstract][Full Text] [Related]
4. Measurement of circulating miRNA-125a exhibits good value in the management of etanercept-treated psoriatic patients.
Pei D; Cao J; Qin G; Wang X
J Dermatol; 2020 Feb; 47(2):140-146. PubMed ID: 31820498
[TBL] [Abstract][Full Text] [Related]
5. Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study.
Gordon KB; Armstrong AW; Han C; Foley P; Song M; Wasfi Y; You Y; Shen YK; Reich K
J Eur Acad Dermatol Venereol; 2018 Nov; 32(11):1940-1949. PubMed ID: 29706008
[TBL] [Abstract][Full Text] [Related]
6. Low levels of emotional awareness predict a better response to dermatological treatment in patients with psoriasis.
Consoli SM; Rolhion S; Martin C; Ruel K; Cambazard F; Pellet J; Misery L
Dermatology; 2006; 212(2):128-36. PubMed ID: 16484819
[TBL] [Abstract][Full Text] [Related]
7. Plasma miR-126 expression correlates with risk and severity of psoriasis and its high level at baseline predicts worse response to Tripterygium wilfordii Hook F in combination with acitretin.
Duan Y; Zou J; Mao J; Guo D; Wu M; Xu N; Zhou J; Zhang Y; Guo W; Jin W
Biomed Pharmacother; 2019 Jul; 115():108761. PubMed ID: 31100542
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis.
van den Reek JMPA; Coenen MJH; van de L'Isle Arias M; Zweegers J; Rodijk-Olthuis D; Schalkwijk J; Vermeulen SH; Joosten I; van de Kerkhof PCM; Seyger MMB; Zeeuwen PLJM; de Jong EMGJ
Br J Dermatol; 2017 May; 176(5):1288-1296. PubMed ID: 27564082
[TBL] [Abstract][Full Text] [Related]
9. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-146a and microRNA-146b deficiency correlates with exacerbated disease activity, and their longitude increment relates to etanercept response in psoriasis patients.
Shen H; Wang D; Zhan M; Ding H; Zhao H
J Clin Lab Anal; 2022 Feb; 36(2):e24198. PubMed ID: 34952998
[TBL] [Abstract][Full Text] [Related]
11. Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study.
Talamonti M; Galluzzo M; Bernardini N; Caldarola G; Persechino S; Cantoresi F; Egan CG; Potenza C; Peris K; Bianchi L
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1737-1744. PubMed ID: 29776016
[TBL] [Abstract][Full Text] [Related]
12. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
[TBL] [Abstract][Full Text] [Related]
13. Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies.
Griffiths CEM; Fava M; Miller AH; Russell J; Ball SG; Xu W; Acharya N; Rapaport MH
Psychother Psychosom; 2017; 86(5):260-267. PubMed ID: 28903122
[TBL] [Abstract][Full Text] [Related]
14. Initial experience with routine administration of etanercept in psoriasis.
de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD
Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
[TBL] [Abstract][Full Text] [Related]
15. PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis.
Carrera CG; Dapavo P; Malagoli P; Naldi L; Arancio L; Gaiani F; Egan CG; Di Mercurio M; Cattaneo A
J Dermatolog Treat; 2018 Aug; 29(5):481-486. PubMed ID: 29058948
[TBL] [Abstract][Full Text] [Related]
16. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.
Gottlieb AB; Lacour JP; Korman N; Wilhelm S; Dutronc Y; Schacht A; Erickson J; Zhang L; Mallbris L; Gerdes S
J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):679-685. PubMed ID: 27696577
[TBL] [Abstract][Full Text] [Related]
17. Cost Per Additional Responder Associated With Ixekizumab and Etanercept in the Treatment of Moderate-to-Severe Psoriasis.
Feldman SR; Foster SA; Zhu B; Burge R; Al Sawah S; Goldblum OM
J Drugs Dermatol; 2017 Dec; 16(12):1246-1252. PubMed ID: 29240860
[TBL] [Abstract][Full Text] [Related]
18. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
Al-Mutairi N; Nour T
Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
[TBL] [Abstract][Full Text] [Related]
19. Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BioCAPTURE cohort.
Zweegers J; Roosenboom B; van de Kerkhof PC; van den Reek JM; Otero ME; Atalay S; Kuijpers AL; Koetsier MI; Arnold WP; Berends MA; Weppner-Parren L; Bijen M; Njoo MD; Mommers JM; van Lümig PP; Driessen RJ; Kievit W; de Jong EM
Br J Dermatol; 2017 Mar; 176(3):786-793. PubMed ID: 27454758
[TBL] [Abstract][Full Text] [Related]
20. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT).
Lebwohl M; Blauvelt A; Paul C; Sofen H; Węgłowska J; Piguet V; Burge D; Rolleri R; Drew J; Peterson L; Augustin M
J Am Acad Dermatol; 2018 Aug; 79(2):266-276.e5. PubMed ID: 29660425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
